N-terminal pro-brain natriuretic peptide independently predicts protein energy wasting and is associated with all-cause mortality in prevalent HD patients

American Journal of Nephrology

Volumn 29, Issue 6, 2009, Pages 516-523

  Guo, Qunying ^a   Bárány, Peter ^a   Qureshi, Abdul Rashid ^a   Snaedal, Sunna ^a   Heimbürger, Olof ^a   Stenvinkel, Peter ^a   Lindholm, Bengt ^a,b   Axelsson, Jonas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Chronic kidney disease; N terminal pro brain natriuretic peptide; Protein energy wasting; Subjective global assessment

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; INTERLEUKIN 6; SERUM ALBUMIN; SOMATOMEDIN C; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRIP STRENGTH; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL; WASTING SYNDROME;

AGED; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; PROTEIN-ENERGY MALNUTRITION; ROC CURVE; SWEDEN;

EID: 57449119759     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000185628     Document Type: Article

References (42)

1. Felker GM, Petersen JW, Mark DB: Natriuretic peptides in the diagnosis and management of heart failure. Cmaj 2006;175:611-617.
2. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, Nielsen LB: Increased cardiac bnp expression associated with myocardial ischemia. Faseb J 2003;17: 1105-1107.
3. Sullivan DR, West M, Jeremy R: Utility of brain natriuretic peptide (bnp) measurement in cardiovascular disease. Heart Lung Circ 2005;14: 78-84.
4. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlov J: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-2116.
5. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, Lamb EJ: B-type natriuretic peptide (bnp) and amino-terminal probnp in patients with ckd: Relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005;46:610-620.
6. Racek J, Kralova H, Trefil L, Rajdl D, Eiselt J: Brain natriuretic peptide and n-terminal probnp in chronic haemodialysis patients. Nephron Clin Pract 2006;103:c162-c172.
7. Khan IA, Fink J, Nass C, Chen H, Christenson R, deFilippi CR: N-terminal pro-b-type natriuretic peptide and b-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 2006;97:1530-1534.
8. David S, Kumpers P, Seidler V, Biertz F, Haller H, Fliser D: Diagnost ic value of N-ter-minal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis. Nephrol Dial Transplant 2008;23:1370-1377.
9. Wang AY, Lam CW, Yu CM, Wang M, Chan IH, Zhang Y, Lui SF, Sanderson JE: N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007;18: 321-330.
10. Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J: Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000;15:953-960.
11. Shahab I, Nolph KD: MIA syndrome in peritoneal dialysis: prevention and treatment. Contrib Nephrol 2006;150:135-143.
12. Tonbul HZ, Demir M, Altintepe L, Guney I, Ekrem Y, Turk S, Yeksan M, Yildiz A: Malnutrition-inflammation-atherosclerosis (MIA) syndrome components in hemodialysis and peritoneal dialysis patients. Ren Fail 2006;28:287-294.
13. Bergstrom J: Inflammation, malnutrition, cardiovascular disease and mortality in endstage renal disease. Pol Arch Med Wewn 2000;104:641-643.
14. Carrero JJ, Qureshi AR, Axelsson J, Avesani CM, Suliman ME, Kato S, Barany P, SnaedalJonsdottir S, Alvestrand A, Heimburger O, Lindholm B, Stenvinkel P: Comparison of nutritional and inf lammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 2007;85:695-701.
15. Davies SJ, Phillips L, Naish PF, Russell GI: Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002;17:1085-1092.
16. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergstrom J: Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 1998;53:773-782.
17. Stenvinkel P: Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 2001;19:53-61.
18. Stenvinkel P: Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant 2002;17(suppl 8):33-38;discussion 40.
19. Pecoits-Filho R, Lindholm B, Stenvinkel P: The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrol Dial Transplant 2002;17(suppl 11):28-31.
20. Greaves SC, Sharpe DN: Cardiovascular disease in patients with end-stage renal failure. Aust NZ J Med 1992;22:153-159.
21. Huting J, Schutterle G: Cardiovascular factors influencing survival in end-stage renal disease treated by continuous ambulatory peritoneal dialysis. Am J Cardiol 1992;69: 123-127.
22. London GM, Marchais SJ, Metivier F, Guerin AP: Cardiovascular risk in end-stage renal disease: vascular aspects. Nephrol Dial Transplant 2000;15(suppl 5):97-104.
23. Arici M, Walls J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001;59:407-414.
24. Satyan S, Light R P, Agarwal R: Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007;50:1009-1019.
25. Sole MJ, Jeejeebhoy KN: Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care 2000;3:417-424.
26. Carr JG, Stevenson LW, Walden JA, Heber D: Prevalence and hemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1989;63: 709-713.
27. Schocken DD, Holloway JD, Powers PS: Weight loss and the heart. Effects of anorexia nervosa and starvation. Arch Intern Med 1989;149:877-881.
28. Sliwa K, Woodiwiss A, Kone VN, Candy G, Badenhorst D, Norton G , Zambakides C, Peters F, Essop R: Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 2004;109:750-755.
29. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-241.
30. Anker SD, von Haehling S: Inflammatory mediators in chronic heart failure: an overview. Hear t 2004;90:464-470.
31. Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS: Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest 1997;100:2777-2782.
32. Mitch WE, Goldberg AL: Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996;335: 1897-1905.
33. Aguilera A, Codoceo R, Selgas R, Garcia P, Picornell M, Diaz C, Sanchez C, Bajo MA: Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters. Nephrol Dial Transplant 1998;13:1476-1483.
34. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD: Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353: 1838-1842.
35. Wang AY, Sanderson J, Sea MM, Wang M, Lam CW, Li PK, Lui SF, Woo J: Important factors other than dialysis adequacy associated with inadequate dietary protein and energy intakes in patients receiving maintenance peritoneal dialysis. Am J Clin Nutr 2003;77: 834-841.
36. Kopple JD: Pathophysiology of protein-energy wasting in chronic renal failure. J Nutr 1999;129:247S-251S.
37. Cheng LT, Tang W, Wang T: Strong association between volume status and nutritional status in peritoneal dialysis patients. Am J Kidney Dis 2005;45:891-902.
38. Paniagua R, Amato D, Mujais S, Vonesh E, Ramos A, Correa-Rotter R, Horl WH: Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial. Clin J Am Soc Nephrol 2008;3: 407-415.
39. Provan SA, Angel K, Odegard S, Mowinckel P, Atar D, Kvien TK: The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study. Arthritis Res Ther 2008;10:R70.
40. Entman ML, Michael L, Rossen RD, Dreyer WJ, Anderson DC, Taylor AA, Smith CW: Inflammation in the course of early myocardia l ischemia. FASEB J 1991;5: 2529-2537.
41. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM: The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984;69: 250-258.
42. Pitt B: Blockade of the renin-angiotensin system. Effect on mortality in patients with left ventricular systolic dysfunction. Cardiol Clin 1994;12:101-114.